Related references
Note: Only part of the references are listed.Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study
Vincenzo Di Noia et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Dynamic Immune/Inflammation Precision Medicine: The Good and the Bad Inflammation in Infection and Cancer
Jean-Francois Rossi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
Christine M. Cramer-van der Welle et al.
SCIENTIFIC REPORTS (2021)
Inflammatory Markers in Cancer Immunotherapy
Deepak Ravindranathan et al.
BIOLOGY-BASEL (2021)
Explaining multivariate molecular diagnostic tests via Shapley values
Joanna Roder et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2021)
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer
David Waterhouse et al.
LUNG CANCER (2021)
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Elizabeth Dudnik et al.
ONCOIMMUNOLOGY (2021)
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach
Julia Grigorieva et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis
Ticiana A. Leal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
J. R. Brahmer et al.
ANNALS OF ONCOLOGY (2020)
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis
Jie Liu et al.
ONCOIMMUNOLOGY (2020)
Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests
Julia Grigorieva et al.
CLINICAL MASS SPECTROMETRY (2020)
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Ernest Nadal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
Ryul Kim et al.
CLINICAL LUNG CANCER (2019)
Real-world Performance of Blood-Based Proteomic Profiling in Frontline Immunotherapy Treatment in Advanced stage NSCLC
P. Rich et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database
Gaurav Singal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients
Mary Jo Fidler et al.
BMC CANCER (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
Cassia Rita Pereira da Veiga et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma
Hestia Mellert et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC
P. R. Walker et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non-Small Cell Lung Cancer
Francesco Grossi et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hallmarks of response to immune checkpoint blockade
Alexandria P. Cogdill et al.
BRITISH JOURNAL OF CANCER (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer and systemic inflammation: treat the tumour and treat the host
C. S. D. Roxburgh et al.
BRITISH JOURNAL OF CANCER (2014)
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc et al.
LANCET ONCOLOGY (2014)
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors
Enrico Milan et al.
JOURNAL OF PROTEOMICS (2012)
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Chiara Lazzari et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
David P. Carbone et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
Fumiko Taguchi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Share Paper
